Replies to post #4383 on Navidea Biopharmaceuticals Inc (NAVB)

[insideoutsideupside]

The quarterly filings is the best place to get information on additional financial instruments. Here's the warrant summary for the 10K.

Series-Conversion price-shares-expiration

Series X 0.46 8,333,333 December 2013
Series AA 0.97 2,400,000 July 2014
Series BB 2.00 300,000 July 2015
Series EE 2.375 134,211 August 2015
Series FF 1.97 30,000 December 2015
Series GG 2.10 333,333 December 2016


However there have been changes in later Qs, so I need to amend my previous information on warrant conversion.

The Series X and AA warrants have been extinguished and replaced with preferred Bs. so money is not due to Navidea at the end of the year.

Preferred Bs convert to common on 12/31/2013, unless the waiver for expiration is extended again.

From the latest 10Q

9. Stock Warrants

In March 2013, Montaur exercised 3,000,000 of their Series X warrants in exchange for the issuance of 3,000,000 shares of our common stock, resulting in gross proceeds of $1,380,000.

In June 2013, pursuant to the Exercise Agreement, Montaur exercised its Series X Warrant and Series AA Warrant for 2,364.9 shares of the Company’s Series B which are convertible into 7,733,223 shares of our common stock in the aggregate (3,270 shares of common stock per preferred share). The warrants were exercised on a cashless basis by cancelling a portion of the indebtedness outstanding under the Montaur Loan Agreement equal to $4,781,333, the aggregate exercise price of the warrants.

Also in June 2013 and pursuant to the GECC and MidCap Loan Agreement, the Company issued to GECC and MidCap Series HH Warrants to purchase an aggregate of 301,205 shares of our common stock at an exercise price of $2.49 per share, expiring in June 2023.

In addition, in June 2013 we issued five-year Series II Warrants to purchase 275,000 shares of our common stock at an exercise price of $3.04 per share to an investment advisory firm in connection with the GECC transaction.

At June 30, 2013, there are 1.4 million warrants outstanding to purchase our common stock. The warrants are exercisable at prices ranging from $1.97 to $3.04 per share with a weighted average exercise price of $2.38 per share.